Stock Yards Bank & Trust Co. Grows Position in AstraZeneca PLC (NASDAQ:AZN)

Stock Yards Bank & Trust Co. boosted its stake in AstraZeneca PLC (NASDAQ:AZN) by 17.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 8,116 shares of the company’s stock after buying an additional 1,224 shares during the period. Stock Yards Bank & Trust Co.’s holdings in AstraZeneca were worth $532,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. Valley National Advisers Inc. lifted its stake in AstraZeneca by 2.2% in the fourth quarter. Valley National Advisers Inc. now owns 23,470 shares of the company’s stock valued at $1,537,000 after buying an additional 508 shares during the last quarter. U.S. Capital Wealth Advisors LLC grew its holdings in shares of AstraZeneca by 25.7% during the fourth quarter. U.S. Capital Wealth Advisors LLC now owns 4,933 shares of the company’s stock worth $323,000 after buying an additional 1,008 shares during the last quarter. Greenleaf Trust increased its position in AstraZeneca by 4.7% in the 4th quarter. Greenleaf Trust now owns 27,104 shares of the company’s stock valued at $1,776,000 after acquiring an additional 1,210 shares during the period. Golden State Equity Partners raised its stake in AstraZeneca by 370.4% during the 4th quarter. Golden State Equity Partners now owns 5,809 shares of the company’s stock valued at $381,000 after acquiring an additional 4,574 shares during the last quarter. Finally, Avantra Family Wealth Inc. acquired a new stake in AstraZeneca during the 4th quarter worth approximately $596,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Down 1.3 %

Shares of NASDAQ AZN opened at $69.86 on Tuesday. The firm’s 50 day moving average price is $67.08 and its 200 day moving average price is $73.85. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. The firm has a market cap of $216.64 billion, a P/E ratio of 33.43, a price-to-earnings-growth ratio of 1.18 and a beta of 0.46. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter in the previous year, the business earned $0.87 earnings per share. The business’s revenue for the quarter was up 18.0% on a year-over-year basis. As a group, sell-side analysts anticipate that AstraZeneca PLC will post 4.13 earnings per share for the current year.

Analysts Set New Price Targets

AZN has been the subject of several recent research reports. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.